CCL2 and atherosclerosis: Correspondingly, interventions targeting monocyte recruitment by disrupting MCP-1/CCL2 (monocyte chemoattractant protein 1) and CCR2 signaling have shown promise in mitigating excessive inflammation and conferring protection in mouse models of myocardial infarction and atherosclerosis [9].